CoChat
Sign Up
Cited by 131Vitamin D Research StudiesBone health and osteoporosis researchParathyroid Disorders and Treatments

Amelioration of osteopenia and hypovitaminosis D by 1alpha -hydroxyvitamin D3 in elderly patients with Parkinson's disease

Open access
Sato, Y., Manabe, S., Kuno, H., Oizumi, K.·1999·Journal of Neurology, Neurosurgery & Psychiatry
DOI 10.1136/jnnp.66.1.64PMC PMC1736147
Open this paper in CoChat — free accountOpen PDF

Abstract

OBJECTIVES: A high prevalence of hip and other fractures in elderly patients with Parkinson's disease has been linked to reduced bone mass arising from a defect of renal synthesis of 1, 25-dihydroxyvitamin D (1, 25-[OH]2D). Treatment with 1alpha-hydroxyvitamin D3 (1alpha(OH)D3; an active form of vitamin D) was evaluated for maintaining bone mass and reducing the incidence of hip and other nonvertebral fractures in patients with Parkinson's disease. METHODS: In a double blind, randomised trial, 86 elderly patients with Parkinson's disease (mean Hoehn and Yahr stage, 3; mean age 70.6 years) were randomised to receive either 1 microg 1alpha(OH)D3 daily (treatment group, n=43) or a placebo (n=43) for 18 months. Bone mineral densities in the second metacarpals were determined by computed radiographic densitometry. Serum bone turnover indices were measured serially, and incidence of nonvertebral fractures was recorded. RESULTS: Bone mineral densities decreased 1.2% in the treatment group compared with 6.7% in the placebo group during 18 months (p<0.0001). At baseline in both groups, the serum concentration of 1, 25-[OH]2D was reduced. Parathyroid hormone was abnormally increased in 15 patients (17%) and correlated negatively with serum 25-hydroxyvitamin D, indicating compensatory hyperparathyroidism. Eight patients sustained fractures (six at the hip and two at other sites) in the placebo group, and one hip fracture occurred among treated patients (odds ratio 9.8; p=0.0028). CONCLUSION: By increasing serum 1, 25-[OH]2D concentrations, treatment with 1alpha(OH)D3 can reduce the risk of hip and other non-vertebral fractures in osteoporotic elderly patients with Parkinson's disease by slowing the loss of bone mineral densities.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1136/jnnp.66.1.64This paper is marked retracted.

Cites

32 of 33 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • Three affected trial reports were cited in the review by Binks and Dobson as evidence for the benefit of vitamin D and bisphosphonates in people with Parkinson's disease.

    “Three affected trial reports8 15 16 were cited in the review by Binks and Dobson34 (one citation, 2017) as evidence for the benefit of vitamin D and bisphosphonates in people with Parkinson’s disease.”

    From An investigation into the impact and implications of published papers from retracted research: systematic search of affected literature (2019) · cites this paper as [8]

    The Methods and fracture-results sections identify this paper as a trial of active vitamin D3 in elderly people with Parkinson’s disease and report fewer fractures in the treatment group. Our copy does not establish that three trial reports were affected or that Binks and Dobson cited them; this trial also did not test bisphosphonates. Page numbers are unavailable in the indexed passages. (LLM, conf=0.82)

    Experimental — accuracy not yet measured

  • In their review of vitamin D and Parkinson's disease, Peterson et al base their conclusions almost entirely on data from four affected trial reports.

    “In their review of vitamin D and Parkinson’s disease, Peterson et al 33 (16 citations, 2017) base their conclusions almost entirely on data from four affected trial reports.8 9 15 16”

    From An investigation into the impact and implications of published papers from retracted research: systematic search of affected literature (2019) · cites this paper as [8]

  • A guideline from AHRQ excluded one trial report from its review of interventions to prevent falls in older people because the report did not focus on the outcome of interest, that is, the rate of falls or number of fallers, despite what appeared to be relevant falls data in the affected trial report.

    “A guideline from AHRQ57 excluded one trial report8 from its review of interventions to prevent falls in older people. The reason for exclusion was that the report did not focus on the outcome of interest, that is, the rate of falls or number of fallers, despite what appeared to be relevant falls data in the affected trial report.”

    From An investigation into the impact and implications of published papers from retracted research: systematic search of affected literature (2019) · cites this paper as [8]

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

2 retracted

Flagged first, then by citations

Research works printed but not linked: 4

  1. Sato Y, Maruoka H, Oizumi K. Amelioration of hemiplegia- associated osteopenia over four years following stroke by 1 -hydroxyvitamin D3 and calcium supplementation. Stroke 1997;28:736-9.
  2. Inoue T, Orimo H, Koshikawa S, et al. Acronym of improved microdensitometry (computed x ray densitom- etry) [letter]. Journal of Bone and Mineral Metabolism 1994; 12:145.
  3. Koller WC, Glatt S, Vetere-Overfield B, et al. Falls and Par- kinson's disease. Clin Neuropharmacol 1989;12:98-105.
  4. Matsumoto C, Kushida K, Sato Y, et al. The second meta- carpal bone density microdensitometry method (in Japa- nese). Seikeigeka 1992;43:1140-6.

Cited by

Sorted by citations

Related

Authors
Sato, Y., Manabe, S., Kuno, H., & Oizumi, K.
Affiliations
Kurume University (JP)
ORCID
Manabe, S.
Venue
Journal of Neurology, Neurosurgery & Psychiatry
Publisher
BMJ
Published
1999-01-01
Volume
66
Issue
1
Pages
64-68
ISSN
0022-3050 (ISSN-L)
DOI
10.1136/jnnp.66.1.64
PMC
PMC1736147
OpenAlex
W2082859231
Cited by
131
References
33
Citations by year
2025: 2 · 2024: 1 · 2023: 3 · 2022: 3 · 2020: 1 · 2019: 5 · 2018: 2 · 2017: 3 · 2016: 4 · 2015: 2 · 2014: 3 · 2013: 11 · 2012: 4
FWCI
2.33
Type
journal article
Language
en
Status
Retracted
Update notices
retraction (2017-08-28)
Open access
Locations
  • Journal of Neurology Neurosurgery & Psychiatry (publishedVersion)
  • PubMed Central (publishedVersion)
  • PubMed (publishedVersion)
Topics
  • Health Sciences › Medicine › Pathology and Forensic Medicine › Vitamin D Research Studies
  • Health Sciences › Medicine › Orthopedics and Sports Medicine › Bone health and osteoporosis research
  • Health Sciences › Medicine › Nephrology › Parathyroid Disorders and Treatments
Keywords
Parkinson's disease, 1α-hydroxyvitamin D3, 1,25-dihydroxyvitamin D, osteopenia, vitamin D deficiency, bone mineral density, hip fracture, non-vertebral fractures, osteoporosis, older adults, parathyroid hormone, bone turnover
MeSH terms
Aged, Aged, 80 and over, Bone Diseases, Metabolic, Double-Blind Method, Female, Hip Fractures, Humans, Hydroxycholecalciferols, Male, Parathyroid Hormone, Parkinson Disease, Vitamin D Deficiency, Bone Density

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review